Hengrui Camrelizumab UNION Phase 3 Trial Shows Better 3-Year EFS Than Standard Treatment in Locally Advanced Rectal Cancer

Hengrui's camrelizumab UNION phase 3 trial met its key secondary EFS endpoint, with short-course radiotherapy followed by camrelizumab plus CAPOX showing better 3-year EFS than standard treatment in locally advanced rectal cancer. Investigator-assessed 3-year EFS was 91.3% vs 77.4%, HR 0.33 (95% CI 0.15–0.71), p=0.0029; BIRC-assessed EFS was 87.2% vs 73.7%, HR 0.41 (95% CI 0.21–0.81).